Allergy Therapeutics (AGY) — Cash Flow Quality Index
Allergy Therapeutics (AGY) has a Cash Flow Quality Index of 0.56x as of December 2021. Operating cash flow of GBX3.71 Million is below net income of GBX6.67 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore AGY total asset value for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Allergy Therapeutics Cash Flow Quality Index (2003–2021)
Historical Cash Flow Quality Index for Allergy Therapeutics across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check AGY tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Allergy Therapeutics (2003–2021)
Year-by-year earnings quality comparison for Allergy Therapeutics. For live market cap and the full company financial profile, see Allergy Therapeutics market capitalisation.
| Year | Quality Index | Operating CF (GBX) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 2.95x | GBX8.52 Million | GBX2.89 Million | ▲ +69.7% |
| 2020 | 1.74x | GBX12.28 Million | GBX7.06 Million | ▲ +7.7% |
| 2019 | 1.62x | GBX5.60 Million | GBX3.47 Million | ▼ -94.4% |
| 2015 | 28.92x | GBX3.12 Million | GBX108.00K | ▲ +886.1% |
| 2014 | 2.93x | GBX2.17 Million | GBX741.00K | ▼ -47.9% |
| 2013 | 5.63x | GBX2.43 Million | GBX432.00K | ▲ +25.1% |
| 2012 | 4.50x | GBX2.88 Million | GBX640.00K | ▲ +125.5% |
| 2011 | -17.63x | GBX-2.03 Million | GBX115.00K | ▼ -1607.8% |
| 2010 | 1.17x | GBX1.70 Million | GBX1.46 Million | ▼ -4.6% |
| 2004 | 1.22x | GBX1.91 Million | GBX1.56 Million | ▼ -21.7% |
| 2003 | 1.56x | GBX2.10 Million | GBX1.34 Million | — |